Cerevel Therapeutics

We are a biopharmaceutical company focused on unraveling the mysteries of the brain to treat neuroscience diseases.

General Information
Company Name
Cerevel Therapeutics
Founded Year
2018
Location (Offices)
Cambridge, United States +1
Founders / Decision Makers
Tony Coles - CEO & Chairperson of the Board of Directors Kathleen Tregoning - Chief Corporate Affairs Officer Raymond Sanchez - CMO Abraham Ceesay - President John Renger - CSO Susan Altschuller - Chief Financial Officer Orly Mishan - CBO
Number of Employees
373
Industries
Biotechnology, Health and Wellness, Pharmaceutical
Funding Stage
Post Ipo Equity
Social Media

Cerevel Therapeutics - Company Profile

Cerevel Therapeutics is a biopharmaceutical company founded in 2018 and headquartered in the Greater Boston area, United States. The company is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. Cerevel Therapeutics focuses on developing new therapies for disorders of the central nervous system (CNS), with a portfolio of experimental neuroscience therapies including three clinical-stage compounds and several pre-clinical compounds. These are designed to target a broad range of CNS disorders such as Parkinson’s, Alzheimer’s, epilepsy, schizophrenia, and addiction. In October 2023, Cerevel Therapeutics received a substantial $450.00M post-IPO equity investment. The company's formation in 2018 was made possible through a partnership between Bain Capital and Pfizer. As a biopharmaceutical company at the forefront of neuroscience research, Cerevel Therapeutics is well-positioned to make significant strides in the treatment of CNS disorders and potentially make a meaningful impact on global healthcare.

Taxonomy: biopharmaceutical company, neuroscience, CNS disorders, clinical-stage compounds, pre-clinical compounds, Parkinson’s disease, Alzheimer’s disease, epilepsy, schizophrenia, addiction, Bain Capital, Pfizer, neurocircuitry, receptor selectivity, pipeline

Funding Rounds & Investors of Cerevel Therapeutics (6)

View All
Funding Stage Amount No. Investors Investors Date
Post-IPO Equity $450.00M - 11 Oct 2023
Post-IPO Debt $300.00M - 12 Aug 2022
Post-IPO Equity $350.00M - 01 Jul 2021
Post-IPO Equity $125.00M 2
Bain Capital, investor in Cerevel Therapeutics's Post-IPO Equity round Novaquest Capital Management, investor in Cerevel Therapeutics's Post-IPO Equity round
13 Apr 2021
Post-IPO Equity $320.00M 10
RA Capital Management, investor in Cerevel Therapeutics's Post-IPO Equity round Invus, investor in Cerevel Therapeutics's Post-IPO Equity round T. Rowe Price, investor in Cerevel Therapeutics's Post-IPO Equity round Fidelity, investor in Cerevel Therapeutics's Post-IPO Equity round Novalis LifeSciences, investor in Cerevel Therapeutics's Post-IPO Equity round Perceptive Advisors, investor in Cerevel Therapeutics's Post-IPO Equity round Rock Springs Capital, investor in Cerevel Therapeutics's Post-IPO Equity round
Surveyor Capital, Sphera Global Healthcare Fund +1 		29 Jul 2020

View All 6 Funding Rounds

Latest News of Cerevel Therapeutics

View All

No recent news or press coverage available for Cerevel Therapeutics.

Similar Companies to Cerevel Therapeutics

View All
OrsoBio - Similar company to Cerevel Therapeutics
OrsoBio Advancing first-in-class therapies to restore energy homeostasis
Graviton Bioscience - Similar company to Cerevel Therapeutics
Graviton Bioscience Curing Disease through Restored Homeostasis
BrainCells - Similar company to Cerevel Therapeutics
BrainCells Pioneering biopharmaceutical solutions to enhance neuron growth and address CNS disorders with advanced clinical-stage programs
Azevan Pharmaceuticals - Similar company to Cerevel Therapeutics
Azevan Pharmaceuticals Innovative therapies for stress, mood, and behavior disorders
VITA PHARMA LIMITED - Similar company to Cerevel Therapeutics
VITA PHARMA LIMITED Pioneering advanced treatments to address significant unmet medical needs in chronic kidney disease, diabetes, atherosclerosis, and Alzheimer's disease.